🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9109 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Sep 2026, 03:16 UTC
9109
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 10 Arizona 8 Florida 8 Colorado 6 Texas 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Regeneron Pharmaceuticals2 Pfizer1 Novartis Pharmaceuticals1 K36 Therapeutics, Inc.1 Merck Sharp & Dohme LLC1
State
California10 Arizona8 Florida8 Colorado6 Texas5
All 32 states
Target enrolment
to
10 of 9109 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
NCT07594106Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals
Phase 1/2
265
Arizona, California, Florida, Illinois, Texas
2026-07-20
Active, closed
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
NCT07285694Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.
Phase 1/2
190
California, Colorado, Iowa, Kansas, Minnesota, New York, Washington
2026-01-09
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Active, closed
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
NCT06894511Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Phase 2
7
Arizona, California, Florida, Nebraska
2025-09-11
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Dendreon
Phase 2
400
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Michigan
2023-10-02
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
Exelixis
Phase 1
1,394
Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana
2021-12-14
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Alaska, Arizona, California, Florida, Louisiana, Maryland, Michigan, Nebraska
2021-03-18
Recruiting
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT03972657Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals
Phase 1/2
345
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, Michigan, Minnesota
2019-08-12
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Arizona, California, Connecticut, Kansas, Kentucky, Maryland, Massachusetts, Nebraska
2018-04-17
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.